Company intelligence / Profile preview

Hexin

Changchun, Jilin, Chinahexin-technology.com ↗

Ownership: Private
Development stage: Commercial

Overview

XY003 is an innovative anti-tumor drug utilizing synthetic lethality to target DNA damage repair-deficient tumors. It has received IND approval from China's CDE/NMPA. The compound shows broader efficacy than PARP inhibitors and can treat advanced solid tumors that are resistant or insensitive to current therapies. The company's antiviral program includes drugs with superior efficacy over ganciclovir against herpes viruses. Their rapid microbial detection methods are widely adopted in multiple sectors.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small moleculeDeviceBiologic
Industry: Biotech

Beyond the preview

Go deeper on Hexin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hexin.

Explore the full profile